RE:Where We Are NowHey Sanfran...as always yours is a very well written POV.
I agree there have been many very positive actions taken over the past year and the actions are accelerating in the past few months. They have built a very strong science team (with many key connections throughout the scientific and BP community and they keep adding on to it. The new CEO at Zenith seems to have a bio that suggests possible IPOs at Zenith. Clearly the brain power and belief in RVX-208 and Zenith epigenetics platforms is supported by the big hitters.
Regarding the diabetes trial results press release it is most unfortunate that they used the phrase "Patients (n=23) with pre-diabetes mellitus (also called metabolic syndrome) were enrolled in the study and given 200 mg/day RVX-208 for a short duration of only 4 weeks. The preliminary results were not consistent with their hypothesis."
If this is a completely accurate statement then it says they are barking up the wrong tree AND I don't believe that at all based on ASSURE and SUSTAIN post hocs plus all of the scientific finding pasted around on this site that strongly suggest this underlying model has strong support for all kinds os diseases and chronic conditions.
That statment underlined above should have been stated in the most clear and accurate phrazing possible. It was worded as a dead end and a failure AND that is not the case. The post hocs on this small sample may reveal biomarkers that were becoming evident in the 4 week test that are indicators of ApoA1 dvelopment and subsequent glucose enhancement at the 12 week period.
Anyway, it is better for the posters with scientific knowledge to provide perspective on this.
My point as always is that RVX has not learned a thing since that CC top line dissaster on June 2013. They made the very same mistake again and that is foolish, inaccurate and frustrating.
So now we need to wait for the post hoc recovery from this and it won't be easy in spite of all of their great work.
I guess I'm ranting again but it is frustrating.
Toinv